Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer Triple Negative|Breast Cancer Stage II|Breast Cancer Stage III|Breast Cancer Invasive
Sponsor: Emory University
Collaborators: National Cancer Institute (NCI)